Suzhou Ribo Life Science Co. Ltd. Class H 6938

Insilico Medicine ("Insilico", 03696.HK), a biotechnology company powered by generative artificial intelligence, today announced that the company has entered a strategic collaboration agreement with Suzhou Ribo Life Science Co., Ltd. ("Ribo", 06938.HK), a globally leading clinical-stage company in oligonucleotide therapeutics. Building upon the automation, intelligence and scalability capabilities of Insilico's LifeStar 2 laboratory, the two parties will further deepen the existing experimental

Suzhou Ribo Life Science Co., Ltd. ("Ribo", 06938.HK) announced that the Company has entered into a strategic collaboration agreement with Insilico Medicine ("Insilico", 03696.HK). Both parties will leverage their respective core strengths in siRNA drug development and AI-powered drug discovery to conduct in-depth collaboration in target discovery, drug molecule design and optimization, AI-assisted drug development and clinical translation. The two parties will advance the rollout of demonstrati

Stock performance and recent context Suzhou Ribo Life Science (SEHK:6938) has drawn investor attention after mixed recent returns, with the stock flat over the past day, slightly higher over the past week, but down over the past month and past 3 months. See our latest analysis for Suzhou Ribo Life Science. Stepping back from the recent softness, Suzhou Ribo Life Science’s share price return has declined 13.6% over the past month and 25.7% year to date, which may indicate fading momentum as...

Madrigal (MDGL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Madrigal is eying an expansion of Rezdiffra’s capabilities via combination with precision siRNA gene silencing.